Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.